Methacrylic Acid

Methacrylic Acid

SCHEMBL11900544

C=C(C)C(=O)O.C=C(C)C(=O)O.O=C(O)S.O=C(O)S.O=C(O)S

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.44
FFAR3 O14843 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.31
THPO P40225 1/20 0.31
TGFBR1 P36897 1/20 0.31
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methacrylic Acid SCHEMBL27939761 0.89
Methacrylic Acid SCHEMBL182989 0.89 TDP1 (0.53) TDP1FFAR3LCKFYNALDH1A1
Methacrylic Acid SCHEMBL11235035 0.89 TDP1 (0.53) TDP1FFAR3LCKFYNALDH1A1
Methacrylic Acid SCHEMBL66252 0.89 TDP1 (0.53) TDP1FFAR3LCKFYNALDH1A1
Methacrylic Acid SCHEMBL13234423 0.89
Methacrylic Acid SCHEMBL15043 0.89 TDP1 (0.53) TDP1FFAR3LCKFYNALDH1A1
Methacrylic Acid SCHEMBL195316 0.89 TDP1 (0.53) TDP1FFAR3LCKFYNALDH1A1
Methacrylic Acid SCHEMBL491341 0.89 TDP1 (0.53) TDP1FFAR3LCKFYNALDH1A1
Methacrylic Acid SCHEMBL15005463 0.89 TDP1 (0.53) TDP1FFAR3LCKFYNALDH1A1
Methacrylic Acid SCHEMBL2230382 0.89 TDP1 (0.53) TDP1FFAR3LCKFYNALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758597-B2 Reducing polymerization-induced shrinkage stress by reversible addition-fragmentation chain transfer THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2017-09-12 US disclosed
US-8877830-B2 Stress relief for crosslinked polymers THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2014-11-04 US disclosed
US-20130096219-A1 REDUCING POLYMERIZATION-INDUCED SHRINKAGE STRESS BY REVERSIBLE ADDITION-FRAGMENTATION CHAIN TRANSFER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-04-18 US disclosed
US-20120202917-A1 Stress Relief for Crosslinked Polymers NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202917-A1 Stress Relief for Crosslinked Polymers DDIT3, ERCC4, ERCC5 TDP1 849/4885FFAR3 651/4885LCK 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.